William Blair & Company
INTS icon

William Blair & Company’s Intensity Therapeutics INTS Stock Holding History

William Blair & Company’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,208
Closed -$12.4K – 1970
2025
Q4 		$12.4K Sell
1,208
-304
-20% -$3.08K ﹤0.01% 1769
2025
Q3 		$9.18K Hold
1,512
– – ﹤0.01% 1766
2025
Q2 		$11.6K Hold
1,512
– – ﹤0.01% 1718
2025
Q1 		$74.5K Hold
1,512
– – ﹤0.01% 1537
2024
Q4 		$66.5K Hold
1,512
– – ﹤0.01% 1574
2024
Q3 		$144K Hold
1,512
– – ﹤0.01% 1495
2024
Q2 		$185K Buy
+1,512
New +$172K ﹤0.01% 1433

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

William Blair & Company's INTS Position: Q1 2026 in Review

William Blair & Company sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 1,208 shares — an estimated $12.4K sold.

William Blair & Company first reported a position in INTS in Q2 2024 and held it in 7 quarters. The position peaked at $185K in Q2 2024. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • William Blair & Company reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • William Blair & Company sold 1,208 Intensity Therapeutics shares in Q1 2026, an estimated $12.4K.
  • William Blair & Company first reported a position in Intensity Therapeutics in Q2 2024 and held it in 7 quarters.
  • William Blair & Company's Intensity Therapeutics position peaked at $185K in Q2 2024.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.